New diabetes drug rongliflozin tested in patients with kidney problems
NCT ID NCT05374343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a single dose of the drug rongliflozin in 32 Chinese adults with type 2 diabetes who had normal, mildly, or moderately reduced kidney function. Researchers measured how the drug moved through the body and how it affected blood sugar and urine glucose. The goal was to see if kidney function changes how the drug works, which could guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rongliflozin (a drug taken by mouth)
What this could lead to
If successful, this could help doctors understand how rongliflozin works in people with type 2 diabetes and kidney problems, potentially leading to better blood sugar control.
What could go wrong
This is a very early (Phase 1) study with only 32 people, so results may not apply to everyone. The drug may not work as well in those with kidney impairment, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ping Feng
Chengdu, Sichuan, 610041, China